Revelation Biosciences, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
REVB Nasdaq 3840 www.revbiosciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Revelation Biosciences, Inc.

Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jul 21st, 2026 2:05 pm
Revelation Biosciences Announces Adoption of Stockholder Rights Plan - Jul 10th, 2026 2:05 pm
Revelation Biosciences Expands Acute Kidney Injury Advisory Board - Jun 1st, 2026 7:00 am
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders - May 11th, 2026 7:00 am
REVB Poised for Big Year - May 8th, 2026 6:04 am
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026 - May 7th, 2026 2:15 pm
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board - Apr 6th, 2026 7:00 am
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study - Mar 30th, 2026 7:00 am
REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference - Mar 24th, 2026 7:00 am
Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference - Mar 19th, 2026 7:00 am
REVB 2026 Starts in Positive Fashion - Feb 27th, 2026 4:12 am
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 - Feb 26th, 2026 2:15 pm
REVB Comes to Agreement with FDA - Jan 29th, 2026 3:16 am
Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 - Jan 26th, 2026 7:55 am
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds - Jan 23rd, 2026 12:10 pm
BC-Most Active Stocks - Jan 23rd, 2026 8:30 am
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI - Jan 21st, 2026 6:30 am
REVB: 2026 Shaping Up to be Great Year - Jan 16th, 2026 6:21 am
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) - Jan 14th, 2026 7:00 am
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 12th, 2026 3:00 pm